Connect with us


Adolescent TB Patients Suffer Fatal Neglect—Doctors



Adolescent TB Patients Suffer Fatal Neglect—Doctors

Adolescent TB Patients Suffer Fatal Neglect—Doctors

As a group of Khayelitsha schoolchildren living with drug-resistant tuberculosis (DR-TB) today unveiled an artwork commemorating their battles against the disease, the international humanitarian organisation, Doctors Without Borders (MSF), has warned that adolescents are being fatally neglected in the response to TB and DR-TB in South Africa, and calls on the Department of Basic Education (DBE) to expedite plans to implement school-based TB education and TB screening in collaboration with the Department of Health (DOH).

Medical staff who work in the MSF DR-TB projects in Khayelitsha, Western Cape, and King Cetshwayo District, KwaZulu-Natal, have spoken of critical gaps in the country’s response, including low TB literacy, too few TB screening opportunities, difficulties identifying adolescents who have been exposed to DR-TB and linking them to diagnosis, and limited access to better, more tolerable DR-TB treatments. Consequently this underdiagnosed population misses the opportunity to realise improved treatment outcomes.

According to Dr Jenny Hughes, MSF’s TB doctor in Khayelitsha, ‘an estimated 10 percent (of approximately 650’000 cases of DR-TB worldwide) occur among children and adolescents, and although young people respond well to treatment, thousands die from this disease each year, largely due to lack of access to improved diagnostic techniques and more tolerable treatment for young people. South Africa is no exception.’

The country’s new National Strategic Plan for HIV, TB and STIs (2017-2022) recommends providing health services such as TB screening in schools, although this much-needed activity is likely to stall until the Department of Basic Education finalizes and implements its 2015 Draft Policy on HIV, STIs and TB. MSF calls on the DBE to have this strategy approved without further delay.

After-hours strategies are also required for tracing adolescents who have been in contact with TB and DR-TB patients, and linking them to diagnostic and treatment services. Upward of 50% of all DR-TB cases in Khayelitsha are due to direct transmission of already drug-resistant strains. In South Africa, a strategic focus on tracing children under age 5 may have led to other vulnerable populations being neglected, including adolescents.

“Adolescents are usually at school during the daytime when health department officials do TB screening in households. Those who do get screened and referred to clinics for diagnosis find queues that keep them out of school for hours, so many turn away. So on the one hand we need wider screening for TB in schools, and on the other we need youth-friendly facilities with after-hours services,” says Xoliswa Harmans, a DR-TB counsellor at MSF Khayelitsha.

17 year old Sinethemba Kuse was diagnosed late, just days before Christmas in 2015, and later found that her TB strain was drug resistant (DR-TB).

“I didn’t know about TB. Nobody ever talked about it in school and I didn’t know that I could go to my local clinic to have a TB screening,” says Kuse, who is the subject of the portrait that will be unveiled on World TB Day.

Once diagnosed with DR-TB adolescents must face the same harsh treatment regimen that is used for adults, which includes a painful daily injection for months and side effects of the medications that can have catastrophic consequences for their growth and development.

“Studies conducted in the Western Cape show that up to 24% of children and adolescents on the injectable DR-TB agent that is currently in standard use develops hearing loss, which obviously impacts everything from schoolwork to social life. More tolerable treatments substituting an injectable agent with promising new medicines like delamanid are urgently required in order to make treatment more tolerable and also improve adolescent treatment outcomes,’ says Dr Hughes.

On World TB Day MSF will join a list of signatories on an open letter to delamanid manufacturer Otsuka, calling on the Japanese pharmaceutical company to urgently make this important new drug more widely available.

Kuse is one of the first South Africans under the age of 18 to have been initiated on delamanid, which is currently only available to approximately 1% of those in need of the drug. She is doing very well and her doctors expect she will be cured this year. Kuse says she agreed to sit for the portrait because she wants other youth to know that TB can be cured. Prints of the 2m tall artwork will be presented to select clinics and schools in Khayelitsha, along with Kuse’s story. The piece was created by local artist Claude Chandler, using word stamps made by Kuse and other adolescent DR-TB patients. The patients were asked to think of a word that expressed their experience of living with DR-TB. Kuse’s word was ‘hope’.

Modupe Gbadeyanka is a fast-rising journalist with Business Post Nigeria. Her passion for journalism is amazing. She is willing to learn more with a view to becoming one of the best pen-pushers in Nigeria. Her role models are the duo of CNN's Richard Quest and Christiane Amanpour.

Click to comment

Leave a Reply


Nigeria Surpasses 30% COVID-19 Vaccination Milestone



COVID-19 vaccination milestone

By Modupe Gbadeyanka

A new report has revealed that Nigeria has surpassed the milestone of fully vaccinating 30 per cent of its total population as a result of a sustained COVID-19 vaccination rollout in recent months.

Nigeria has maintained the COVID-19 vaccine rollout through campaigns and initiatives with the support of stakeholders, including Gavi, the Vaccine Alliance. COVAX, which Gavi co-leads with the Coalition for Epidemic Preparedness Innovations (CEPI), WHO and UNICEF, has supplied over 91 million COVID-19 vaccines to Nigeria (about 65 per cent of all vaccines received) and over 669 million to the African continent.

The country has also developed an integrated micro-plan featuring routine immunisation alongside COVID-19 vaccinations with a bottom-up approach taking into account individual state’s plans.

Recall that in January 2022, the country reported less than 3 per cent coverage, but dedicated efforts by the government and stakeholders in rolling out relevant strategies to sustain COVID-19 vaccination amidst competing health priorities have caused the COVID-19 vaccination milestone.

According to Gavi, key drivers behind the success of this year’s drive include leadership and improved coordination at the local, state and national levels, as well as innovation, such as the increase in mobile vaccination sites.

With more teams being supported to take the vaccines to communities rather than wait for visits to facilities, missed opportunities are being reduced.

The country also adopted a strategy to track the performance of the vaccination teams in the various states through daily call-in data. The performance of states is being ranked, and this is disseminated daily on social media and provides healthy competition across the states.

Nigeria has also set up COVID-19 Crisis Communication Centre (CRICC) at the national and state levels, ensuring targeted demand-generation activities were adopted and rolled out across the country.

The country has also integrated a service delivery approach with teams empowered to provide multiple arrays of services – COVID-19 vaccination, and routine immunization, ensuring that other key health services were not neglected.

Dr Richard Mihigo, Director of COVID-19 Vaccine Delivery, Coordination and Integration at Gavi, the Vaccine Alliance, which leads on procurement and delivery at scale for COVAX, said, “Nigeria has become a case study on how to roll out COVID-19 vaccines at scale and speed and at the same time, catch up on routine immunization programmes.

“The country’s surveillance systems are efficient and precise, enabling monitoring of trends as well as promptly responding to counter vaccine misinformation increasing acceptability of the vaccines.”

Continue Reading


Streamlining and Increasing Pharmacy Inventory Workflow



pharmacy inventory workflow

Pharmacies are an essential part of the healthcare system. However, managing pharmacy inventory is difficult for pharmacists due to the complexity of tracking stock levels and expiration dates. Streamlining and increasing pharmacy inventory workflows help make this process more efficient. Here are some tips that can help pharmacies maximize their inventory workflow.

Use Pharmacy Inventory Solutions

With comprehensive pharmacy inventory solutions, pharmacists will keep track of all their supplies in an organized manner. Such solutions offer a wide range of features to help streamline the inventory process and make it easier for pharmacies to manage their inventory. Features such as automated order fulfilment, real-time stock visibility, and streamlined processes help reduce mistakes and save time.

Automate Reordering Processes

Automating the reordering process is another way to increase pharmacy workflow efficiency. By automating the ordering process, pharmacies no longer have to manually place orders or check on availability when items are out of stock. This allows pharmacists to focus on more important tasks instead of wasting time on mundane administrative chores. Additionally, automated reordering systems allow better tracking and forecasting of inventory needs.

Implement Barcode Scanning

A barcode scanner is very helpful for pharmacies in tracking inventory levels and identifying items quickly. This helps to reduce errors and streamline the process of counting inventory. Barcode scanners are also used with automated reordering solutions to ensure orders are placed accurately and on time.

Additionally, barcode scanners track expiration dates and alert staff when items need to be restocked or thrown away. This way, pharmacists don’t have to worry about expired products on the shelves.

Utilize Analytics Tools

Analytics tools provide pharmacies with valuable insight into their inventory workflow and help them identify areas where they may need improvements. With analytics, pharmacists can track trends in sales data and stock levels and monitor customer buying patterns. That allows them to anticipate customer needs better and adjust their ordering processes accordingly. It also helps pharmacists track certain items’ performance and decide what products best suit their business model.

Proper Employee Training

Employees are the foundation of any successful business, and proper employee training is essential for ensuring that pharmacy inventory workflow processes are efficient. Pharmacists should ensure that their staff is properly trained to use the various systems and tools. Training should also include tips on how to keep up with stock levels, expiration dates, and drug interactions. With the right training, employees help prevent errors and save time when managing the pharmacy’s inventory.

Invest in Quality Control

Pharmacists should also invest in quality control processes to ensure that their inventory remains updated. Quality control procedures help identify discrepancies or issues with the inventory and alert staff when problems occur. This helps prevent expired items from reaching customers or mistakes made with orders. Quality control processes also help pharmacies save money by preventing waste and ensuring that items are ordered in the right quantities.

Focus on Customer Service

Finally, pharmacies should focus on providing excellent customer service. This involves ensuring that customers have accurate information about their medications and being available whenever they need help.

Pharmacists should also take the time to answer customer questions and address any concerns they may have. This way, pharmacists ensure that customers leave satisfied, leading to better sales and repeat business.

Implementing the strategies mentioned above helps streamline and increase pharmacy inventory workflow. Automating reordering processes, utilizing analytics tools, investing in quality control, and focusing on customer service are great ways to improve efficiency and increase profits. Pharmacies will operate more smoothly and efficiently with the right systems and processes.

Continue Reading


Research Shows Interorganisational Deals Boost Drug Discovery, Innovation



interorganisational deal

By Adedapo Adesanya

In a recent study published in the journal Drug Discovery Today, a team of scientists at Ritsumeikan University in Japan analysed the changing trends in pharmaceutical industries to spotlight the role of interorganisational collaborations in promoting drug discovery and innovation.

Discovering new drugs has become increasingly rare for independent large pharmaceutical companies in recent times. With numbers showing that almost 60 per cent of new drugs are discovered through mergers and acquisitions and drug licensing.

Now, the university researchers shed light on the recent trends of spinouts from academia and investments in the US and Europe, foreshadowing a promising shift in the industry’s interorganisational deal networks to improve research and development productivity in the future.

“It is a challenging feat to launch a new drug in the market, given the low probability of success during the research and development (R&D) phase and the high costs involved. In recent times, industry trends in external innovation for drug discovery are rapidly changing.  With an improved understanding of disease biology, decision-making can be more streamlined through the effective use of scientific information,” a statement made available to Business Post said.

Led by Associate Professor Kota Kodama of Ritsumeikan University, the team is uncovering how the trends in interorganisational deals in the pharmaceutical industry are changing to improve R&D productivity and drug discovery.

“The network structure of innovation creation in the pharmaceutical industry has changed with the increasing emergence of start-up companies spinning out from academia and research institutions as players in the source of innovation,” explains Dr Kodama, while discussing their investigations into these changing trends and the results of which were made available online on December 27, 2022, and published in volume 28 issue 3 of the journal Drug Discovery Today on March 1, 2023.

Their research suggests that the knowledge necessary for breakthrough innovation in drug discovery is more often than not obtained through alliance networks.

Over the past decade, large research-based pharmaceutical companies have used research collaborations, innovation incubators, academic centres of excellence, public-private partnerships, mergers and acquisitions (M&As), drug licensing, and corporate venture capital funds as typical methods for external innovation.

The researchers now aim to define the changes in the network structure and nature of such alliances that have occurred over the past decade to provide future strategic insights for industry and academic players involved in drug discovery.

Using data from the Cortellis Competitive Intelligence database, the researchers identified nearly 50,000 deals of various kinds related to pharmaceutical R&D across pharmaceutical, digital health software, animal drug, and medical device companies to uncover trends in the creation of new drugs for human use.

They also studied the trends of 13 of the largest pharmaceutical companies with annual revenues of more than $10 billion, who saw an improvement in their CAGR (compound annual growth rate) since 2015.

The researchers noticed that the rising CAGR correlated to a significant change in M&A-related deals after 2015, indicating that M&A-related deals drive revenue growth for large pharmaceutical companies.

Furthermore, the number of organizations involved in interorganisational deals has been increasing yearly from 2012 to 2021. Although the number of organizations involved and the number of deals may be increasing, the density of the deal networks is decreasing annually, suggesting that networks are becoming more non-cohesive.

The concentration of business relationships between organizations of certain areas in the network changed to dispersion around 2015, and new networks connecting different groups started to form after 2017.

These trends are an important illustration of how the industry landscape is gradually evolving away from the traditional network in which large pharmaceutical companies drove drug discovery output. Now, interorganisational deals among more diverse players have become active and are driving R&D productivity for startups in biotechnology and pharmaceuticals.

A clear increase in the number of academia-owned spinouts of advanced technology and expansion of investment in start-ups is a positive sign. The emergence of new chemical modalities, such as biologics, oligonucleotides, and peptides that differ from traditional small molecule drug discovery, indicate remarkable changes that have taken place over the past two decades.

The trend of increased financing for start-up companies in personalized drug development is beneficial for patent creation and will positively impact innovation creation in the coming years.

“The presence of academia to support the technologies of these start-ups is becoming very important, and government and private support and investment in this area are boosting innovation. Our study shows that such medium- and long-term support may ultimately benefit the health and well-being of humankind,” Dr Kodama noted.

interorganisational deal

Continue Reading
%d bloggers like this: